Immunoassays Compared to Improve Diagnosis of Chagas Disease

Up to 99% of CD cases in the Americas and more than 90% in Europe are undiagnosed. A key barrier is the complexity of the diagnostic process, which is hampered by the lack of a gold standard, availability of multiple types of assays with varying sensitivity and specificity, and the sheer difficulty of detecting the parasite in the chronic phase of the disease.

Scientists associated the Colombian National Institute of Health (Bogota, Colombia) used a panel of 501 serum samples obtained from whole blood and the samples reflected a broad spectrum of CD patients in Colombia. Patients ranged in age from 1 to 81, but only seven were under 18 years old. Mean patient age was 39.3 years and was younger in blood donors (22.3) than patients tested in public health laboratories (49.4).

Samples were characterized as positive (n = 256) or negative (n = 245) using standard procedures based on four serological assays: an in-house enzyme-linked immunosorbent assay (ELISA), optic density ≥ 0.300; an in-house immunofluorescence assay (IFA), dilution ≥ 1:32; an indirect hemagglutination; and immunoblots of trypomastigote excreted-secreted antigens.

The scientists assessed seven commercially available assays and found that five of seven assays exhibited sensitivity >98% while six showed specificity >97%. A total antigen ELISA paired with a recombinant assay provided similar performance to the current diagnostic process. Six of six assays tested proved capable of detecting different Trypanosoma cruzi genetic lineages. Of the 501 samples, 85.2% were correctly classified by all seven immunoassays; 222/256 positive samples (86.7%) and 202/245 (83.7%) negative samples.

The authors concluded that their study demonstrated the utility of systematically evaluating T. cruzi assays, using WHO standards, to validate national guidelines for CD diagnosis, strengthen quality control of diagnostic tools, and promote international standardization. A simplified testing process with two commercial assays could perform comparably to the previous process, reducing cost and accessibility barriers and facilitating national scale-up. The study was published in the October 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Colombian National Institute of Health